IGC Pharma, Inc. (IGC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, IGC Pharma reported revenue of $1.3M, down 5.5% from $1.3M the year before. Net income was -$7.1M (a -560.3% net margin), or -$0.09 per diluted share. Gross margin was 48.7% and operating margin was -585.8%. Operating activities generated -$4.8M of cash, leaving -$4.9M of free cash flow. At fiscal year end, IGC Pharma held $8.7M in total assets against $2.4M in total liabilities, including $405,000 of cash and equivalents.
Open the full interactive IGC Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
IGC Pharma Key Stats
| Share Price | $0.27 |
|---|---|
| Market Cap | $27.1M |
| Revenue YoY Growth | -5.5% |
| 52-Week Range | $0.24 – $0.42 |
| Shares Outstanding | 100.3 million (basic, 2027 Q1) |
IGC Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $898,000 | $397,000 | $911,000 | $1.3M | $1.3M |
| Gross Profit | $115,000 | $113,000 | $194,000 | $442,000 | $733,000 | $619,000 |
| Operating Income | -$6.9M | -$8.7M | -$15.4M | -$11.6M | -$9.8M | -$7.4M |
| Pre-Tax Income | -$7.3M | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$7.3M | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M |
| Diluted EPS | -$0.19 | -$0.21 | — | — | — | -$0.09 |
IGC Pharma Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $330,000 | $328,000 | $191,000 | $265,000 |
| Net Income | -$1.2M | -$1.6M | -$1.8M | -$2.9M |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.03 |
IGC Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.3M | $14.5M | $10.5M | $3.2M | $1.2M | $405,000 |
| Current Assets | $17.8M | $23.5M | $15.1M | $6.5M | $3.7M | $2.9M |
| Total Assets | $29.0M | $35.9M | $26.8M | $17.2M | $9.9M | $8.7M |
| Current Liabilities | $1.9M | $2.4M | $2.4M | $1.9M | $2.3M | $2.3M |
| Total Long-Term Debt | — | $276,000 | $144,000 | $141,000 | $137,000 | $134,000 |
| Total Liabilities | $2.4M | $3.1M | $2.9M | $2.3M | $2.6M | $2.4M |
| Shareholders' Equity | $26.5M | $32.8M | $23.9M | $14.9M | $7.3M | $6.3M |
IGC Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$8.7M | -$10.8M | -$7.5M | -$7.0M | -$5.2M | -$4.8M |
| Cash From Investing | -$9.5M | $3.4M | -$742,000 | -$235,000 | -$317,000 | -$442,000 |
| Cash From Financing | -$59,000 | $14.7M | $4.1M | $100,000 | $3.5M | $4.5M |
| Free Cash Flow | -$13.1M | -$12.3M | -$7.7M | -$7.4M | -$5.3M | -$4.9M |
Figures from IGC Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full IGC Pharma financials page for every line item.
IGC Pharma Company Profile
| Ticker | IGC |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Potomac, Maryland |
| Incorporated in | Maryland |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001326205 |
Frequently Asked Questions
What was IGC Pharma's revenue in fiscal 2025?
IGC Pharma (IGC) reported revenue of $1.3M for fiscal 2025.
What is IGC Pharma's annual revenue history?
IGC Pharma's annual revenue by fiscal year: 2020: $4.1M; 2021: $898,000; 2022: $397,000; 2023: $911,000; 2024: $1.3M; 2025: $1.3M.
What was IGC Pharma's net income in fiscal 2025?
IGC Pharma reported net income of -$7.1M for fiscal 2025.
What was IGC Pharma's earnings per share (EPS) in fiscal 2025?
IGC Pharma's diluted EPS was -$0.09 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did IGC Pharma generate in fiscal 2025?
IGC Pharma generated -$4.9M of free cash flow in fiscal 2025.
What was IGC Pharma's revenue last quarter?
In its most recent reported quarter (2027 Q1), IGC Pharma reported revenue of $265,000.
How much debt does IGC Pharma have?
IGC Pharma reported $134,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of IGC Pharma are outstanding?
IGC Pharma reported a weighted average of 100.3 million basic shares outstanding in 2027 Q1.
What is IGC Pharma's market cap?
Based on its latest closing price, IGC Pharma (IGC) has a market capitalization of about $27.1M.
When does IGC Pharma's fiscal year end?
IGC Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is IGC Pharma headquartered?
IGC Pharma lists its business address in Potomac, Maryland in its SEC filings.